Psychedelic Compounds

Executive summary: 2C-x denotes a family of synthetic phenethylamine psychedelics defined by a 2,5-dimethoxyphenethylamine scaffold with a variable 4-position substituent (“X”). Across the class, the best-supported core mechanism is serotonergic psychedelic activity mediated primarily through 5-HT2A receptor signalling, with many compounds also showing functional activity at 5-HT2C and (importantly for safety discussions) 5-HT2B. 2C-B (4-bromo-2,5-dimethoxyphenethylamine) functions as the empirical archetype because it dominates the modern controlled-human literature relative to other 2C analogues. Clinically, 2C-x remains a “mechanism-rich, evidence-thin” space. The human evidence base is concentrated in small mechanistic studies: (i) early non-controlled observational work assessing acute subjective and physiological effects and (saliva/oral-fluid) pharmacokinetics; (ii) controlled, within-subject, placebo-controlled comparisons to psilocybin in healthy volunteers; and (iii) the beginning of biomarker-enabled Phase I crossover work that explicitly benchmarks 2C-B against MDMA and psilocybin and includes plasma oxytocin and BDNF endpoints. This makes 2C-x scientifically legible (mechanistically comparable) but not yet clinically “actionable” for patient indications in the way the psilocybin and MDMA programmes are. Regulatorily, 2C-B is tightly controlled: it is Schedule I under US federal law (listed as 4-bromo-2,5-dimethoxyphenethylamine) and has been internationally controlled since 2001 via placement in Schedule II of the 1971 Convention on Psychotropic Substances. In the UK it is Class A and placed in Schedule 1 of the Misuse of Drugs Regulations, reflecting “no recognised therapeutic use” under current UK frameworks. Canada lists 2C-B in Schedule III, and Australia lists it in Schedule 9 of the Poisons Standard. This landscape has two consequences for 2C-x: (i) research remains licence- and infrastructure-intensive; (ii) commercial strategies that depend on routine prescribing are structurally disadvantaged relative to rescheduled or late-stage agents. Why attention is warranted now: the broader regulatory and commercial “centre of gravity” for serotonergic psychedelics is shifting. On 17 February 2026, Compass Pathways reported its second positive Phase III trial for synthetic psilocybin in treatment-resistant depression, including quantified Week 6 MADRS separations, rapid-onset claims, and an intention to pursue an NDA on a rolling basis. In parallel, a German-led European consortium (named publicly by MIND Foundation as including SPRIN-D, Usona, and ZI Mannheim) describes a planned Phase III/HTA reimbursement-oriented trial (“DiMension”) that remains in preparation and is explicitly seeking public and philanthropic funding. Against that backdrop, the 2C-x field has simultaneously matured methodologically: biomarker panels (oxytocin/BDNF), validated PK methods in plasma, and 7T resting-state fMRI mapping for 2C-B have appeared or progressed. Taken together, the moment is scientifically timely (tools exist to characterise 2C-x properly) but translationally constrained (pathways to near-term clinical adoption remain uncertain).

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

A traditional South American plant brew containing DMT and MAO inhibitors, researched for its therapeutic potential in addiction and depression.

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

The S-enantiomer of ketamine, approved as a prescription nasal spray for treatment-resistant depression and suicidal ideation.

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

A potent classic ergoline psychedelic known for its long-lasting effects and being investigated for anxiety, depression, and cluster headaches.

MDMA (3,4‑methylenedioxymethamphetamine; proposed INN: midomafetamine) is a fully synthetic, ring‑substituted amphetamine (phenethylamine family) originally synthesised at entity["company","Merck","darmstadt, germany"] in 1912 as an intermediate in other medicinal chemistry work. In contemporary neuropsychopharmacology it is classified as an entactogen/empathogen rather than a classic psychedelic, because its acute subjective and behavioural effects are dominated by monoaminergic release rather than primary 5‑HT2A agonism. At the synapse, MDMA is transported by SERT (and to a lesser extent NET/DAT), reverses transporter flux, and mobilises vesicular monoamines via VMAT2, producing substantial increases in extracellular serotonin alongside measurable increases in noradrenaline and dopamine. In controlled human studies this pharmacology maps onto heightened positive mood, affiliative/prosocial effects and reduced threat responsivity, with comparatively limited perceptual disturbance and typically no frank hallucinosis at clinical‑range doses. MDMA’s near‑term clinical significance centres on its use as a pharmacological catalyst for intensive, manualised psychotherapy in post‑traumatic stress disorder (PTSD). Across two pivotal Phase III, multi‑site, randomised, double‑blind, placebo‑controlled trials (MAPP1: NCT03537014; MAPP2: NCT04077437), MDMA‑assisted therapy produced larger reductions in clinician‑rated PTSD severity (CAPS‑5) than identical psychotherapy with placebo, with moderate‑to‑large between‑group effect sizes (d=0.91 in MAPP1; d=0.7 in MAPP2) and parallel improvements in functional impairment (Sheehan Disability Scale). The adverse‑event profile in these trials was dominated by transient sympathomimetic and somatic effects (e.g., blood pressure/heart‑rate increases, jaw tension, nausea, sweating), with no deaths reported. In 2024, the regulatory narrative changed materially. The entity["organization","FDA","us medicines regulator"]’s entity["organization","PDAC","fda advisory committee"] voted 9–2 that the available data did not demonstrate effectiveness for PTSD and 10–1 that benefits did not outweigh risks even with a proposed Risk Evaluation and Mitigation Strategy (REMS), citing concerns including functional unblinding/expectancy effects, incomplete safety characterisation (including for abuse‑relevant events), and uncertainty regarding durability. The FDA subsequently issued a Complete Response Letter for NDA 215455 (midomafetamine capsules plus assisted therapy), declining approval and requesting, in effect, an additional well‑controlled trial design that better captures abuse‑relevant events, durability beyond the Week‑18 endpoint, and generalisability to routine PTSD populations. The sponsor ecosystem has also undergone rapid organisational change. entity["organization","MAPS","psychedelic research nonprofit"]’ commercial subsidiary entity["company","MAPS PBC","subsidiary of maps"] rebranded to entity["company","Lykos Therapeutics","psychedelic drug developer"] in January 2024 alongside an oversubscribed financing reported as >$100m, and following the FDA’s 2024 Complete Response Letter and subsequent restructuring it has been reported to be rebranding again as entity["company","Resilient Pharmaceuticals","psychedelic drug developer"]. Meanwhile, peer‑reviewed Phase II pooled analyses and long‑term follow‑up publications that historically underpinned confidence in durability have been formally retracted by their journal editors due to undisclosed protocol violations at a study site, sharpening regulator and investor focus on governance, documentation, and bias‑resistant trial design.

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Pharmacological details and clinical history for this compound are currently being indexed.

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring substituted tryptamine produced by numerous fungal species, and is also manufactured as a purified synthetic active pharmaceutical ingredient for clinical research and drug development. In humans it acts primarily as a prodrug: it is rapidly dephosphorylated (notably by alkaline phosphatases) to psilocin (4-hydroxy-N,N-dimethyltryptamine), the pharmacologically active compound. Psilocin’s acute psychoactive effects are driven predominantly by agonism at the serotonin 5-HT2A receptor, with meaningful engagement of other serotonergic targets that shape overall phenomenology and downstream neurobiological signalling. Clinically, psilocybin has moved from proof-of-concept psychiatry into late-stage development as a drug-plus-psychological-support intervention. Randomised controlled trials in major depressive disorder (MDD) and treatment-resistant depression (TRD) show that one or two supervised sessions can produce rapid reductions in depressive symptoms and functional impairment, with durability extending well beyond the drug’s pharmacokinetic presence, suggesting that the therapeutic mechanism is not limited to transient receptor stimulation. The clinical and regulatory landscape shifted materially in February 2026, when COMPASS Pathways reported that both of its Phase III TRD trials (COMP005 and COMP006) met their primary endpoints on the Montgomery–Åsberg Depression Rating Scale (MADRS), and stated an intention to engage the FDA on a rolling submission with the goal of filing an NDA in Q4 2026. In parallel, access pathways outside conventional marketing authorisation have expanded: Australia permits psychiatrist prescribing under a controlled framework despite the absence of a TGA-approved psilocybin product; Germany has implemented the European Union’s first psilocybin Compassionate Use Programme for TRD at two specialist centres; and US state-level “regulated access” models (notably Oregon and Colorado) are generating real-world implementation data under non-medical service frameworks. Psilocybin is particularly significant right now because the field is transitioning from “does it work?” to “how can it be deployed safely, reproducibly, and at scale?”. The limiting factors are increasingly operational: therapist training, site logistics for 6–8 hour dosing days, careful risk stratification for suicidality and bipolar-spectrum vulnerability, and credible adverse-event surveillance. This is one driver behind a wave of ‘second-generation’ approaches (for example deuterated psilocin/psilocybin analogues such as CYB003) that aim to preserve clinical benefit while reducing duration, variability, and service burden—although it remains uncertain how reliably such molecular modifications translate into superior real-world effectiveness and safety.